Suchergebnisse - "De Giorgi, Ugo"

PubPharm (596)

51

Feasibility of cabazitaxel in octogenarian prostate cancer patients

enthalten in: Current urology | 2023

von Tralongo, P. | Bordonaro, S. | Di Lorenzo, G. | +11

52

Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer : Final Results From the Phase 2 METEORA-II Randomized Clinical Trial

enthalten in: JAMA oncology | 2023

von Munzone, E. | Regan, M. | Cinieri, S. | +60

53

Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer

enthalten in: International journal of molecular sciences | 2023

von Cursano, M. | Giunta, E. | Scarpi, E. | +10

54

Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations

enthalten in: Minerva urology and nephrology | 2023

von Porta, C. | Bamias, A. | Zakopoulou, R. | +63

55

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma : The ARON-1 Study

enthalten in: Targeted oncology | 2023

von Santoni, M. | Massari, F. | Myint, Z. | +53

56

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2) : a randomised, placebo-controlled, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Agarwal, N. | Azad, A. | Carles, J. | +18

CommentIn: Lancet. 2023 Jul 22;402(10398):266-267. - PMID 37285866

57

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2) : final results of the multicentre, prospective, observational study

enthalten in: EClinicalMedicine | 2023

von Bersanelli, M. | Verzoni, E. | Cortellini, A. | +66

58

Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study

enthalten in: ResearchSquare.com | 2023

von Pisegna, S. | Scagnoli, S. | Toss, A. | +29

59

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2) : a randomised, placebo-controlled, phase 3 trial

enthalten in: The lancet | 22-28 July 2023

von Agarwal, N. | Azad, A. | Carles, J. | +18

60

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

enthalten in: Targeted oncology | 2023

von Santoni, M. | Massari, F. | Myint, Z. | +53